person · Reporting owner

Machiels Alec

Disclosed activity across 2 companies

Tapewire entity: 47333
SEC CIK: 0001496687

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
CREATIVE REALITIES, INC.CREX · Entity 7331	Director	October 01, 2019	October 03, 2019

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

CREATIVE REALITIES, INC.

Report date October 01, 2019 · Filed October 03, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	6,352	Reported balance After 2019-10-01 transaction · row 1 1 source row Row 1 · 2019-10-01 · Grant · Acquired 3,634 · Balance 6,352

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Apellis Pharmaceuticals, Inc.

Report date May 14, 2026 · Filed May 14, 2026

Section 16 reporting ended · disclosed 2026-05-14. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2026-05-14 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-05-14 · Other · Disposed 384,989 · Balance 0 F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among Apellis Pharmaceuticals, Inc. (the "Issuer"), Biogen Inc. ("Parent") and Parent's direct wholly-owned subsidiary, Aspen Purchaser Sub, Inc. ("Purchaser"), dated as of March 31, 2026, the shares of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Purchaser prior to the expiration time of the tender offer were exchanged for: (i) $41.00 per share of Common Stock, net to the seller in cash, without interest and subject to reduction for any applicable tax withholding (the "Cash Amount"), plus (ii) one contractual, non-transferable contingent value right per share of Common Stock (each, a "CVR"), which entitles the holder to receive potential payments of up to an aggregate of $4.00 in cash, without interest and subject to reduction for any applicable tax withholding, upon the achievement of certain specified milestones in accordance F2: (continued from footnote 1) with the terms and conditions of a contingent value rights agreement (the "CVR Agreement" and the Cash Amount plus one CVR, together, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of the filing and acceptance of the certificate of merger relating thereto on May 14, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation (the "Surviving Corporation") and a wholly owned subsidiary of Parent. In the Merger, each share of Common Stock issued and outstanding immediately prior to the Effective Time, subject to certain exceptions, was automatically converted into the right to receive the Offer Price from Purchaser, without interest and subject to reduction for any applicable withholding taxes.
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2026-05-14 transaction · row 5 Account or security details depend on footnotes; rows are not merged. 1 source row Row 5 · 2026-05-14 · Disposition to issuer · Disposed 3,062 · Balance 0 F6: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Converted RSU Award that was subject solely to a time-based vesting schedule (including, for the avoidance of doubt, any Converted RSU Award for which the performance period of any applicable performance metric had already ended) was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award multiplied by (y) the Cash Amount and (ii) one CVR for each share of Common Stock underlying such Converted RSU Award. F7: (continued from footnote 6) Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any "double-trigger" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time, as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement.
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2026-05-14 transaction · row 6 Account or security details depend on footnotes; rows are not merged. 1 source row Row 6 · 2026-05-14 · Disposition to issuer · Disposed 5,744 · Balance 0 F6: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Converted RSU Award that was subject solely to a time-based vesting schedule (including, for the avoidance of doubt, any Converted RSU Award for which the performance period of any applicable performance metric had already ended) was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award multiplied by (y) the Cash Amount and (ii) one CVR for each share of Common Stock underlying such Converted RSU Award. F7: (continued from footnote 6) Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any "double-trigger" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time, as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement.
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2026-05-14 transaction · row 7 Account or security details depend on footnotes; rows are not merged. 1 source row Row 7 · 2026-05-14 · Disposition to issuer · Disposed 7,961 · Balance 0 F6: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Converted RSU Award that was subject solely to a time-based vesting schedule (including, for the avoidance of doubt, any Converted RSU Award for which the performance period of any applicable performance metric had already ended) was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award multiplied by (y) the Cash Amount and (ii) one CVR for each share of Common Stock underlying such Converted RSU Award. F7: (continued from footnote 6) Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any "double-trigger" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time, as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement.
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2026-05-14 transaction · row 8 Account or security details depend on footnotes; rows are not merged. 1 source row Row 8 · 2026-05-14 · Disposition to issuer · Disposed 3,544 · Balance 0 F6: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Converted RSU Award that was subject solely to a time-based vesting schedule (including, for the avoidance of doubt, any Converted RSU Award for which the performance period of any applicable performance metric had already ended) was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award multiplied by (y) the Cash Amount and (ii) one CVR for each share of Common Stock underlying such Converted RSU Award. F7: (continued from footnote 6) Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any "double-trigger" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time, as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement.
Common StockSEC Table I · non-derivative	IndirectIndirect Owner (Bauhaus 1 LLC)	Reported balance After 2026-05-14 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2026-05-14 · Other · Disposed 250,000 · Balance 0 F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among Apellis Pharmaceuticals, Inc. (the "Issuer"), Biogen Inc. ("Parent") and Parent's direct wholly-owned subsidiary, Aspen Purchaser Sub, Inc. ("Purchaser"), dated as of March 31, 2026, the shares of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Purchaser prior to the expiration time of the tender offer were exchanged for: (i) $41.00 per share of Common Stock, net to the seller in cash, without interest and subject to reduction for any applicable tax withholding (the "Cash Amount"), plus (ii) one contractual, non-transferable contingent value right per share of Common Stock (each, a "CVR"), which entitles the holder to receive potential payments of up to an aggregate of $4.00 in cash, without interest and subject to reduction for any applicable tax withholding, upon the achievement of certain specified milestones in accordance F2: (continued from footnote 1) with the terms and conditions of a contingent value rights agreement (the "CVR Agreement" and the Cash Amount plus one CVR, together, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of the filing and acceptance of the certificate of merger relating thereto on May 14, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation (the "Surviving Corporation") and a wholly owned subsidiary of Parent. In the Merger, each share of Common Stock issued and outstanding immediately prior to the Effective Time, subject to certain exceptions, was automatically converted into the right to receive the Offer Price from Purchaser, without interest and subject to reduction for any applicable withholding taxes. F3: The shares are held by Bauhaus 1 LLC, which LLC is held by The Irrevocable Agreement of Trust of Alec Machiels (the "Trust"). The reporting person is the managing member of Bauhaus 1 LLC and the trustee of the Trust.
Common StockSEC Table I · non-derivative	IndirectIndirect Owner (Owned by Spouse)	Reported balance After 2026-05-14 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2026-05-14 · Other · Disposed 11,950 · Balance 0 F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among Apellis Pharmaceuticals, Inc. (the "Issuer"), Biogen Inc. ("Parent") and Parent's direct wholly-owned subsidiary, Aspen Purchaser Sub, Inc. ("Purchaser"), dated as of March 31, 2026, the shares of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Purchaser prior to the expiration time of the tender offer were exchanged for: (i) $41.00 per share of Common Stock, net to the seller in cash, without interest and subject to reduction for any applicable tax withholding (the "Cash Amount"), plus (ii) one contractual, non-transferable contingent value right per share of Common Stock (each, a "CVR"), which entitles the holder to receive potential payments of up to an aggregate of $4.00 in cash, without interest and subject to reduction for any applicable tax withholding, upon the achievement of certain specified milestones in accordance F2: (continued from footnote 1) with the terms and conditions of a contingent value rights agreement (the "CVR Agreement" and the Cash Amount plus one CVR, together, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of the filing and acceptance of the certificate of merger relating thereto on May 14, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation (the "Surviving Corporation") and a wholly owned subsidiary of Parent. In the Merger, each share of Common Stock issued and outstanding immediately prior to the Effective Time, subject to certain exceptions, was automatically converted into the right to receive the Offer Price from Purchaser, without interest and subject to reduction for any applicable withholding taxes. F4: Owned by spouse.
Common StockSEC Table I · non-derivative	IndirectIndirect Owner (Spouse Trust)	Reported balance After 2026-05-14 transaction · row 4 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 4 · 2026-05-14 · Other · Disposed 150,000 · Balance 0 F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among Apellis Pharmaceuticals, Inc. (the "Issuer"), Biogen Inc. ("Parent") and Parent's direct wholly-owned subsidiary, Aspen Purchaser Sub, Inc. ("Purchaser"), dated as of March 31, 2026, the shares of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Purchaser prior to the expiration time of the tender offer were exchanged for: (i) $41.00 per share of Common Stock, net to the seller in cash, without interest and subject to reduction for any applicable tax withholding (the "Cash Amount"), plus (ii) one contractual, non-transferable contingent value right per share of Common Stock (each, a "CVR"), which entitles the holder to receive potential payments of up to an aggregate of $4.00 in cash, without interest and subject to reduction for any applicable tax withholding, upon the achievement of certain specified milestones in accordance F2: (continued from footnote 1) with the terms and conditions of a contingent value rights agreement (the "CVR Agreement" and the Cash Amount plus one CVR, together, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of the filing and acceptance of the certificate of merger relating thereto on May 14, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation (the "Surviving Corporation") and a wholly owned subsidiary of Parent. In the Merger, each share of Common Stock issued and outstanding immediately prior to the Effective Time, subject to certain exceptions, was automatically converted into the right to receive the Offer Price from Purchaser, without interest and subject to reduction for any applicable withholding taxes. F5: On September 7, 2021, the reporting person's spouse transferred 150,000 shares of Apellis Pharmaceuticals, Inc. common stock to her trust, of which the reporting person is the trustee.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.19	Direct	Reported balance After 2026-05-14 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2026-05-14 · Disposition to issuer · Disposed 17,580 · Balance 0 F8: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each outstanding and unexercised option to purchase shares of Common Stock that was vested pursuant to its existing terms or that vested as a result of the transactions contemplated by the Merger Agreement (each, a "Cash-Out Option") and had an exercise price per share that was less than $41.00 (the Cash Amount) was automatically cancelled and converted into the right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such option, multiplied by (y) the excess of the Cash Amount over the exercise price per share of such option and (ii) one CVR for each share of Common Stock underlying such option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.00	Direct	Reported balance After 2026-05-14 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2026-05-14 · Disposition to issuer · Disposed 121,894 · Balance 0 F8: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each outstanding and unexercised option to purchase shares of Common Stock that was vested pursuant to its existing terms or that vested as a result of the transactions contemplated by the Merger Agreement (each, a "Cash-Out Option") and had an exercise price per share that was less than $41.00 (the Cash Amount) was automatically cancelled and converted into the right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such option, multiplied by (y) the excess of the Cash Amount over the exercise price per share of such option and (ii) one CVR for each share of Common Stock underlying such option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.12	Direct	Reported balance After 2026-05-14 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2026-05-14 · Disposition to issuer · Disposed 14,684 · Balance 0 F8: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each outstanding and unexercised option to purchase shares of Common Stock that was vested pursuant to its existing terms or that vested as a result of the transactions contemplated by the Merger Agreement (each, a "Cash-Out Option") and had an exercise price per share that was less than $41.00 (the Cash Amount) was automatically cancelled and converted into the right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such option, multiplied by (y) the excess of the Cash Amount over the exercise price per share of such option and (ii) one CVR for each share of Common Stock underlying such option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.62	Direct	Reported balance After 2026-05-14 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2026-05-14 · Disposition to issuer · Disposed 27,600 · Balance 0 F8: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each outstanding and unexercised option to purchase shares of Common Stock that was vested pursuant to its existing terms or that vested as a result of the transactions contemplated by the Merger Agreement (each, a "Cash-Out Option") and had an exercise price per share that was less than $41.00 (the Cash Amount) was automatically cancelled and converted into the right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such option, multiplied by (y) the excess of the Cash Amount over the exercise price per share of such option and (ii) one CVR for each share of Common Stock underlying such option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.91	Direct	Reported balance After 2026-05-14 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2026-05-14 · Disposition to issuer · Disposed 11,199 · Balance 0 F8: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each outstanding and unexercised option to purchase shares of Common Stock that was vested pursuant to its existing terms or that vested as a result of the transactions contemplated by the Merger Agreement (each, a "Cash-Out Option") and had an exercise price per share that was less than $41.00 (the Cash Amount) was automatically cancelled and converted into the right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such option, multiplied by (y) the excess of the Cash Amount over the exercise price per share of such option and (ii) one CVR for each share of Common Stock underlying such option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $47.28	Direct	Reported balance After 2026-05-14 transaction · row 14 Instrument identity requires review; Table II rows are not merged. 1 source row Row 14 · 2026-05-14 · Disposition to issuer · Disposed 8,554 · Balance 0 F9: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each vested or unvested option with an exercise price per share that was equal to or greater than $45.00 (the Aggregate Amount) was cancelled without consideration and will have no further force or effect.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $51.71	Direct	Reported balance After 2026-05-14 transaction · row 15 Instrument identity requires review; Table II rows are not merged. 1 source row Row 15 · 2026-05-14 · Disposition to issuer · Disposed 7,441 · Balance 0 F9: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each vested or unvested option with an exercise price per share that was equal to or greater than $45.00 (the Aggregate Amount) was cancelled without consideration and will have no further force or effect.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $57.20	Direct	Reported balance After 2026-05-14 transaction · row 16 Instrument identity requires review; Table II rows are not merged. 1 source row Row 16 · 2026-05-14 · Disposition to issuer · Disposed 27,600 · Balance 0 F9: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each vested or unvested option with an exercise price per share that was equal to or greater than $45.00 (the Aggregate Amount) was cancelled without consideration and will have no further force or effect.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $59.86	Direct	Reported balance After 2026-05-14 transaction · row 17 Instrument identity requires review; Table II rows are not merged. 1 source row Row 17 · 2026-05-14 · Disposition to issuer · Disposed 5,748 · Balance 0 F9: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each vested or unvested option with an exercise price per share that was equal to or greater than $45.00 (the Aggregate Amount) was cancelled without consideration and will have no further force or effect.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among Apellis Pharmaceuticals, Inc. (the "Issuer"), Biogen Inc. ("Parent") and Parent's direct wholly-owned subsidiary, Aspen Purchaser Sub, Inc. ("Purchaser"), dated as of March 31, 2026, the shares of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Purchaser prior to the expiration time of the tender offer were exchanged for: (i) $41.00 per share of Common Stock, net to the seller in cash, without interest and subject to reduction for any applicable tax withholding (the "Cash Amount"), plus (ii) one contractual, non-transferable contingent value right per share of Common Stock (each, a "CVR"), which entitles the holder to receive potential payments of up to an aggregate of $4.00 in cash, without interest and subject to reduction for any applicable tax withholding, upon the achievement of certain specified milestones in accordance

F2: (continued from footnote 1) with the terms and conditions of a contingent value rights agreement (the "CVR Agreement" and the Cash Amount plus one CVR, together, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of the filing and acceptance of the certificate of merger relating thereto on May 14, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation (the "Surviving Corporation") and a wholly owned subsidiary of Parent. In the Merger, each share of Common Stock issued and outstanding immediately prior to the Effective Time, subject to certain exceptions, was automatically converted into the right to receive the Offer Price from Purchaser, without interest and subject to reduction for any applicable withholding taxes.

F3: The shares are held by Bauhaus 1 LLC, which LLC is held by The Irrevocable Agreement of Trust of Alec Machiels (the "Trust"). The reporting person is the managing member of Bauhaus 1 LLC and the trustee of the Trust.

F4: Owned by spouse.

F5: On September 7, 2021, the reporting person's spouse transferred 150,000 shares of Apellis Pharmaceuticals, Inc. common stock to her trust, of which the reporting person is the trustee.

F6: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Converted RSU Award that was subject solely to a time-based vesting schedule (including, for the avoidance of doubt, any Converted RSU Award for which the performance period of any applicable performance metric had already ended) was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award multiplied by (y) the Cash Amount and (ii) one CVR for each share of Common Stock underlying such Converted RSU Award.

F7: (continued from footnote 6) Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any "double-trigger" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time, as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement.

F8: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each outstanding and unexercised option to purchase shares of Common Stock that was vested pursuant to its existing terms or that vested as a result of the transactions contemplated by the Merger Agreement (each, a "Cash-Out Option") and had an exercise price per share that was less than $41.00 (the Cash Amount) was automatically cancelled and converted into the right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such option, multiplied by (y) the excess of the Cash Amount over the exercise price per share of such option and (ii) one CVR for each share of Common Stock underlying such option.

F9: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each vested or unvested option with an exercise price per share that was equal to or greater than $45.00 (the Aggregate Amount) was cancelled without consideration and will have no further force or effect.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
April 17, 2023 Filed Apr 18, 2023 20:30 UTC	Apellis Pharmaceuticals, Inc. APLS · Entity 47322	Exercise / conversionCommon Stock	1,250	$2.67	$3,337.50	Disclosure SEC source: 0001127602-23-013129 · form4.xml · nonDerivative · entry 4 Machiels Alec · CIK 0001496687 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 268,891 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · kind: This is a scheduled exercise and sale from 10B5-1 trading plan. Read SEC document
March 17, 2023 Filed Mar 21, 2023 20:35 UTC	Apellis Pharmaceuticals, Inc. APLS · Entity 47322	Exercise / conversionStock Option (Right to Buy) · Derivative	1,250	$0.00 Strike: $2.67	$0.00	Disclosure SEC source: 0001127602-23-010957 · form4.xml · derivative · entry 6 Machiels Alec · CIK 0001496687 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,779 Underlying: Common Stock · 1,250 shares Expires 2023-12-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is a scheduled exercise and sale from 10B5-1 trading plan. F5 · derivative.exercise_date: This option was granted on December 5, 2013 and fully vested. Read SEC document
March 17, 2023 Filed Mar 21, 2023 20:35 UTC	Apellis Pharmaceuticals, Inc. APLS · Entity 47322	SaleCommon Stock	1,250	$64.03	$80,037.50	Disclosure SEC source: 0001127602-23-010957 · form4.xml · nonDerivative · entry 2 Machiels Alec · CIK 0001496687 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 267,641 F1 · kind: This is a scheduled exercise and sale from 10B5-1 trading plan. Read SEC document
March 17, 2023 Filed Mar 21, 2023 20:35 UTC	Apellis Pharmaceuticals, Inc. APLS · Entity 47322	Exercise / conversionCommon Stock	1,250	$2.67	$3,337.50	Disclosure SEC source: 0001127602-23-010957 · form4.xml · nonDerivative · entry 1 Machiels Alec · CIK 0001496687 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 268,891 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is a scheduled exercise and sale from 10B5-1 trading plan. Read SEC document
February 17, 2023 Filed Feb 21, 2023 21:22 UTC	Apellis Pharmaceuticals, Inc. APLS · Entity 47322	Exercise / conversionStock Option (Right to Buy) · Derivative	1,250	$0.00 Strike: $2.67	$0.00	Disclosure SEC source: 0001127602-23-006189 · form4.xml · derivative · entry 6 Machiels Alec · CIK 0001496687 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,029 Underlying: Common Stock · 1,250 shares Expires 2023-12-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is a scheduled exercise and sale from 10B5-1 trading plan. F5 · derivative.exercise_date: This option was granted on December 5, 2013 and fully vested. Read SEC document
February 17, 2023 Filed Feb 21, 2023 21:22 UTC	Apellis Pharmaceuticals, Inc. APLS · Entity 47322	SaleCommon Stock	1,250	$52.38	$65,475.00	Disclosure SEC source: 0001127602-23-006189 · form4.xml · nonDerivative · entry 2 Machiels Alec · CIK 0001496687 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,641 F1 · kind: This is a scheduled exercise and sale from 10B5-1 trading plan. Read SEC document
February 17, 2023 Filed Feb 21, 2023 21:22 UTC	Apellis Pharmaceuticals, Inc. APLS · Entity 47322	Exercise / conversionCommon Stock	1,250	$2.67	$3,337.50	Disclosure SEC source: 0001127602-23-006189 · form4.xml · nonDerivative · entry 1 Machiels Alec · CIK 0001496687 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,891 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is a scheduled exercise and sale from 10B5-1 trading plan. Read SEC document
January 17, 2023 Filed Jan 19, 2023 21:55 UTC	Apellis Pharmaceuticals, Inc. APLS · Entity 47322	Exercise / conversionStock Option (Right to Buy) · Derivative	1,250	$0.00 Strike: $2.67	$0.00	Disclosure SEC source: 0001127602-23-001805 · form4.xml · derivative · entry 6 Machiels Alec · CIK 0001496687 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,279 Underlying: Common Stock · 1,250 shares Expires 2023-12-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is a scheduled exercise and sale from 10B5-1 trading plan. F5 · derivative.exercise_date: This option was granted on December 5, 2013 and fully vested. Read SEC document
January 17, 2023 Filed Jan 19, 2023 21:55 UTC	Apellis Pharmaceuticals, Inc. APLS · Entity 47322	SaleCommon Stock	1,250	$52.42	$65,525.00	Disclosure SEC source: 0001127602-23-001805 · form4.xml · nonDerivative · entry 2 Machiels Alec · CIK 0001496687 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,641 F1 · kind: This is a scheduled exercise and sale from 10B5-1 trading plan. Read SEC document
January 17, 2023 Filed Jan 19, 2023 21:55 UTC	Apellis Pharmaceuticals, Inc. APLS · Entity 47322	Exercise / conversionCommon Stock	1,250	$2.67	$3,337.50	Disclosure SEC source: 0001127602-23-001805 · form4.xml · nonDerivative · entry 1 Machiels Alec · CIK 0001496687 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,891 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is a scheduled exercise and sale from 10B5-1 trading plan. Read SEC document
January 01, 2023 Filed Jan 4, 2023 22:37 UTC	Apellis Pharmaceuticals, Inc. APLS · Entity 47322	GrantStock Option (Right to Buy) · Derivative	7,441	$0.00 Strike: $51.71	$0.00	Disclosure SEC source: 0000899243-23-000675 · doc4.xml · derivative · entry 5 Machiels Alec · CIK 0001496687 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,441 Underlying: Common Stock · 7,441 shares Expires 2030-12-31 F5 · derivative.exercise_date: This option was granted on January 1, 2023. The option vests quarterly on the last day of each quarter from the date of grant, subject to his continued service as a director and expires seven years after the date of grant. Read SEC document
January 01, 2023 Filed Jan 4, 2023 22:37 UTC	Apellis Pharmaceuticals, Inc. APLS · Entity 47322	GrantCommon Stock	3,867	$0.00	$0.00	Disclosure SEC source: 0000899243-23-000675 · doc4.xml · nonDerivative · entry 1 Machiels Alec · CIK 0001496687 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,641 F1 · kind: This restricted stock unit was granted on January 1, 2023. The restricted stock unit will fully vest on the first anniversary of the date of grant, subject to his continued service as a director, or upon later termination of his service as a director at his election. Read SEC document
December 15, 2022 Filed Dec 19, 2022 21:37 UTC	Apellis Pharmaceuticals, Inc. APLS · Entity 47322	Exercise / conversionStock Option (Right to Buy) · Derivative	1,250	$0.00 Strike: $2.67	$0.00	Disclosure SEC source: 0001127602-22-027856 · form4.xml · derivative · entry 6 Machiels Alec · CIK 0001496687 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,529 Underlying: Common Stock · 1,250 shares Expires 2023-12-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option was granted on December 5, 2013 and fully vested. Read SEC document
December 15, 2022 Filed Dec 19, 2022 21:37 UTC	Apellis Pharmaceuticals, Inc. APLS · Entity 47322	SaleCommon Stock	1,250	$52.35	$65,437.50	Disclosure SEC source: 0001127602-22-027856 · form4.xml · nonDerivative · entry 2 Machiels Alec · CIK 0001496687 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 263,774 F1 · kind: This is a scheduled exercise and sale from 10B5-1 trading plan. Read SEC document
December 15, 2022 Filed Dec 19, 2022 21:37 UTC	Apellis Pharmaceuticals, Inc. APLS · Entity 47322	Exercise / conversionCommon Stock	1,250	$2.67	$3,337.50	Disclosure SEC source: 0001127602-22-027856 · form4.xml · nonDerivative · entry 1 Machiels Alec · CIK 0001496687 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,024 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 15, 2022 Filed Nov 17, 2022 21:33 UTC	Apellis Pharmaceuticals, Inc. APLS · Entity 47322	Exercise / conversionStock Option (Right to Buy) · Derivative	1,250	$0.00 Strike: $2.67	$0.00	Disclosure SEC source: 0000899243-22-036194 · doc4.xml · derivative · entry 6 Machiels Alec · CIK 0001496687 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,779 Underlying: Common Stock · 1,250 shares Expires 2023-12-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were effected by pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2021. F3 · derivative.exercise_date: This option was granted on December 5, 2013 and is fully vested. Read SEC document
November 15, 2022 Filed Nov 17, 2022 21:33 UTC	Apellis Pharmaceuticals, Inc. APLS · Entity 47322	SaleCommon Stock	1,250	$48.01	$60,012.50	Disclosure SEC source: 0000899243-22-036194 · doc4.xml · nonDerivative · entry 2 Machiels Alec · CIK 0001496687 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 263,774 F1 · kind: The sales reported on this Form 4 were effected by pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2021. Read SEC document
November 15, 2022 Filed Nov 17, 2022 21:33 UTC	Apellis Pharmaceuticals, Inc. APLS · Entity 47322	Exercise / conversionCommon Stock	1,250	$2.67	$3,337.50	Disclosure SEC source: 0000899243-22-036194 · doc4.xml · nonDerivative · entry 1 Machiels Alec · CIK 0001496687 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,024 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were effected by pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2021. Read SEC document
October 14, 2022 Filed Oct 17, 2022 21:57 UTC	Apellis Pharmaceuticals, Inc. APLS · Entity 47322	Exercise / conversionStock Option (Right to Buy) · Derivative	1,250	$0.00 Strike: $2.67	$0.00	Disclosure SEC source: 0001127602-22-023984 · form4.xml · derivative · entry 6 Machiels Alec · CIK 0001496687 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,029 Underlying: Common Stock · 1,250 shares Expires 2023-12-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is a scheduled exercise and sale from 10B5-1 trading plan. F3 · derivative.exercise_date: This option was granted on December 5, 2013 and fully vested. Read SEC document
October 14, 2022 Filed Oct 17, 2022 21:57 UTC	Apellis Pharmaceuticals, Inc. APLS · Entity 47322	SaleCommon Stock	1,250	$59.31	$74,137.50	Disclosure SEC source: 0001127602-22-023984 · form4.xml · nonDerivative · entry 2 Machiels Alec · CIK 0001496687 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 263,774 F1 · kind: This is a scheduled exercise and sale from 10B5-1 trading plan. Read SEC document
October 14, 2022 Filed Oct 17, 2022 21:57 UTC	Apellis Pharmaceuticals, Inc. APLS · Entity 47322	Exercise / conversionCommon Stock	1,250	$2.67	$3,337.50	Disclosure SEC source: 0001127602-22-023984 · form4.xml · nonDerivative · entry 1 Machiels Alec · CIK 0001496687 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,024 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is a scheduled exercise and sale from 10B5-1 trading plan. Read SEC document
September 15, 2022 Filed Sep 16, 2022 20:03 UTC	Apellis Pharmaceuticals, Inc. APLS · Entity 47322	Exercise / conversionStock Option (Right to Buy) · Derivative	1,250	$0.00 Strike: $2.67	$0.00	Disclosure SEC source: 0001127602-22-022540 · form4.xml · derivative · entry 6 Machiels Alec · CIK 0001496687 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,279 Underlying: Common Stock · 1,250 shares Expires 2023-12-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is a scheduled exercise and sale from 10B5-1 trading plan. F3 · derivative.exercise_date: This option was granted on December 5, 2013 and fully vested. Read SEC document
September 15, 2022 Filed Sep 16, 2022 20:03 UTC	Apellis Pharmaceuticals, Inc. APLS · Entity 47322	SaleCommon Stock	1,250	$66.00	$82,500.00	Disclosure SEC source: 0001127602-22-022540 · form4.xml · nonDerivative · entry 2 Machiels Alec · CIK 0001496687 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 263,774 F1 · kind: This is a scheduled exercise and sale from 10B5-1 trading plan. Read SEC document
September 15, 2022 Filed Sep 16, 2022 20:03 UTC	Apellis Pharmaceuticals, Inc. APLS · Entity 47322	Exercise / conversionCommon Stock	1,250	$2.67	$3,337.50	Disclosure SEC source: 0001127602-22-022540 · form4.xml · nonDerivative · entry 1 Machiels Alec · CIK 0001496687 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,024 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is a scheduled exercise and sale from 10B5-1 trading plan. Read SEC document
August 15, 2022 Filed Aug 16, 2022 21:00 UTC	Apellis Pharmaceuticals, Inc. APLS · Entity 47322	Exercise / conversionStock Option (Right to Buy) · Derivative	1,250	$0.00 Strike: $2.67	$0.00	Disclosure SEC source: 0001127602-22-021109 · form4.xml · derivative · entry 6 Machiels Alec · CIK 0001496687 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,529 Underlying: Common Stock · 1,250 shares Expires 2023-12-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is a scheduled exercise and sale from 10B5-1 trading plan. F3 · derivative.exercise_date: This option was granted on December 5, 2013 and fully vested. Read SEC document
August 15, 2022 Filed Aug 16, 2022 21:00 UTC	Apellis Pharmaceuticals, Inc. APLS · Entity 47322	SaleCommon Stock	1,250	$67.21	$84,012.50	Disclosure SEC source: 0001127602-22-021109 · form4.xml · nonDerivative · entry 2 Machiels Alec · CIK 0001496687 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 263,774 F1 · kind: This is a scheduled exercise and sale from 10B5-1 trading plan. Read SEC document
August 15, 2022 Filed Aug 16, 2022 21:00 UTC	Apellis Pharmaceuticals, Inc. APLS · Entity 47322	Exercise / conversionCommon Stock	1,250	$2.67	$3,337.50	Disclosure SEC source: 0001127602-22-021109 · form4.xml · nonDerivative · entry 1 Machiels Alec · CIK 0001496687 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,024 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is a scheduled exercise and sale from 10B5-1 trading plan. Read SEC document
July 15, 2022 Filed Jul 18, 2022 21:29 UTC	Apellis Pharmaceuticals, Inc. APLS · Entity 47322	Exercise / conversionStock Option (Right to Buy) · Derivative	1,250	$0.00 Strike: $2.67	$0.00	Disclosure SEC source: 0001127602-22-019423 · form4.xml · derivative · entry 6 Machiels Alec · CIK 0001496687 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,779 Underlying: Common Stock · 1,250 shares Expires 2023-12-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is a scheduled exercise and sale from 10B5-1 trading plan. F3 · derivative.exercise_date: This option was granted on December 5, 2013 and fully vested. Read SEC document
July 15, 2022 Filed Jul 18, 2022 21:29 UTC	Apellis Pharmaceuticals, Inc. APLS · Entity 47322	SaleCommon Stock	1,250	$46.33	$57,912.50	Disclosure SEC source: 0001127602-22-019423 · form4.xml · nonDerivative · entry 2 Machiels Alec · CIK 0001496687 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 263,774 F1 · kind: This is a scheduled exercise and sale from 10B5-1 trading plan. Read SEC document
July 15, 2022 Filed Jul 18, 2022 21:29 UTC	Apellis Pharmaceuticals, Inc. APLS · Entity 47322	Exercise / conversionCommon Stock	1,250	$2.67	$3,337.50	Disclosure SEC source: 0001127602-22-019423 · form4.xml · nonDerivative · entry 1 Machiels Alec · CIK 0001496687 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,024 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is a scheduled exercise and sale from 10B5-1 trading plan. Read SEC document
June 15, 2022 Filed Jun 17, 2022 21:02 UTC	Apellis Pharmaceuticals, Inc. APLS · Entity 47322	Exercise / conversionStock Option (Right to Buy) · Derivative	1,250	$0.00 Strike: $2.67	$0.00	Disclosure SEC source: 0001127602-22-017795 · form4.xml · derivative · entry 6 Machiels Alec · CIK 0001496687 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,029 Underlying: Common Stock · 1,250 shares Expires 2023-12-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is a scheduled exercise and sale from 10B5-1 trading plan. F3 · derivative.exercise_date: This option was granted on December 5, 2013 and fully vested. Read SEC document
June 15, 2022 Filed Jun 17, 2022 21:02 UTC	Apellis Pharmaceuticals, Inc. APLS · Entity 47322	SaleCommon Stock	1,250	$39.29	$49,112.50	Disclosure SEC source: 0001127602-22-017795 · form4.xml · nonDerivative · entry 2 Machiels Alec · CIK 0001496687 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 263,774 F1 · kind: This is a scheduled exercise and sale from 10B5-1 trading plan. Read SEC document
June 15, 2022 Filed Jun 17, 2022 21:02 UTC	Apellis Pharmaceuticals, Inc. APLS · Entity 47322	Exercise / conversionCommon Stock	1,250	$2.67	$3,337.50	Disclosure SEC source: 0001127602-22-017795 · form4.xml · nonDerivative · entry 1 Machiels Alec · CIK 0001496687 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,024 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is a scheduled exercise and sale from 10B5-1 trading plan. Read SEC document
May 16, 2022 Filed May 17, 2022 21:26 UTC	Apellis Pharmaceuticals, Inc. APLS · Entity 47322	Exercise / conversionStock Option (Right to Buy) · Derivative	1,250	$0.00 Strike: $2.67	$0.00	Disclosure SEC source: 0001127602-22-014789 · form4.xml · derivative · entry 6 Machiels Alec · CIK 0001496687 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,279 Underlying: Common Stock · 1,250 shares Expires 2023-12-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is a scheduled exercise and sale from 10B5-1 trading plan. F3 · derivative.exercise_date: This option was granted on December 5, 2013 and fully vested. Read SEC document
May 16, 2022 Filed May 17, 2022 21:26 UTC	Apellis Pharmaceuticals, Inc. APLS · Entity 47322	SaleCommon Stock	1,250	$39.18	$48,975.00	Disclosure SEC source: 0001127602-22-014789 · form4.xml · nonDerivative · entry 2 Machiels Alec · CIK 0001496687 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 263,774 F1 · kind: This is a scheduled exercise and sale from 10B5-1 trading plan. Read SEC document
May 16, 2022 Filed May 17, 2022 21:26 UTC	Apellis Pharmaceuticals, Inc. APLS · Entity 47322	Exercise / conversionCommon Stock	1,250	$2.67	$3,337.50	Disclosure SEC source: 0001127602-22-014789 · form4.xml · nonDerivative · entry 1 Machiels Alec · CIK 0001496687 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,024 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is a scheduled exercise and sale from 10B5-1 trading plan. Read SEC document
April 14, 2022 Filed Apr 18, 2022 23:42 UTC	Apellis Pharmaceuticals, Inc. APLS · Entity 47322	Exercise / conversionStock Option (Right to Buy) · Derivative	1,250	$0.00 Strike: $2.67	$0.00	Disclosure SEC source: 0001127602-22-012095 · form4.xml · derivative · entry 6 Machiels Alec · CIK 0001496687 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,529 Underlying: Common Stock · 1,250 shares Expires 2023-12-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is a scheduled exercise and sale from 10B5-1 trading plan. F3 · derivative.exercise_date: This option was granted on December 5, 2013 and fully vested. Read SEC document
April 14, 2022 Filed Apr 18, 2022 23:42 UTC	Apellis Pharmaceuticals, Inc. APLS · Entity 47322	SaleCommon Stock	1,250	$50.90	$63,625.00	Disclosure SEC source: 0001127602-22-012095 · form4.xml · nonDerivative · entry 2 Machiels Alec · CIK 0001496687 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 263,774 F1 · kind: This is a scheduled exercise and sale from 10B5-1 trading plan. Read SEC document
April 14, 2022 Filed Apr 18, 2022 23:42 UTC	Apellis Pharmaceuticals, Inc. APLS · Entity 47322	Exercise / conversionCommon Stock	1,250	$2.67	$3,337.50	Disclosure SEC source: 0001127602-22-012095 · form4.xml · nonDerivative · entry 1 Machiels Alec · CIK 0001496687 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,024 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is a scheduled exercise and sale from 10B5-1 trading plan. Read SEC document
March 15, 2022 Filed Mar 18, 2022 00:59 UTC	Apellis Pharmaceuticals, Inc. APLS · Entity 47322	Exercise / conversionStock option (right to buy) · Derivative	1,250	$0.00 Strike: $2.67	$0.00	Disclosure SEC source: 0000899243-22-011518 · doc4.xml · derivative · entry 6 Machiels Alec · CIK 0001496687 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,779 Underlying: Common Stock · 1,250 shares Expires 2023-12-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale reported in this Form 4 where effected pursuant to a written Rule 10b5-1 trading plan adopted by the reported person. F5 · derivative.exercise_date: This option was granted on December 5, 2013 and is fully vested. Read SEC document
March 15, 2022 Filed Mar 18, 2022 00:59 UTC	Apellis Pharmaceuticals, Inc. APLS · Entity 47322	SaleCommon Stock	1,250	$39.57	$49,462.50	Disclosure SEC source: 0000899243-22-011518 · doc4.xml · nonDerivative · entry 2 Machiels Alec · CIK 0001496687 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,544 F1 · kind: The sale reported in this Form 4 where effected pursuant to a written Rule 10b5-1 trading plan adopted by the reported person. Read SEC document
March 15, 2022 Filed Mar 18, 2022 00:59 UTC	Apellis Pharmaceuticals, Inc. APLS · Entity 47322	Exercise / conversionCommon Stock	1,250	$2.67	$3,337.50	Disclosure SEC source: 0000899243-22-011518 · doc4.xml · nonDerivative · entry 1 Machiels Alec · CIK 0001496687 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,794 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale reported in this Form 4 where effected pursuant to a written Rule 10b5-1 trading plan adopted by the reported person. Read SEC document
February 15, 2022 Filed Feb 16, 2022 21:29 UTC	Apellis Pharmaceuticals, Inc. APLS · Entity 47322	Exercise / conversionStock Option (Right to Buy) · Derivative	1,250	$0.00 Strike: $2.67	$0.00	Disclosure SEC source: 0001127602-22-005298 · form4.xml · derivative · entry 4 Machiels Alec · CIK 0001496687 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,029 Underlying: Common Stock · 1,250 shares Expires 2023-12-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is a scheduled exercise and sale from 10B5-1 trading plan. F3 · derivative.exercise_date: This option was granted on December 5, 2013 and fully vested. Read SEC document
February 15, 2022 Filed Feb 16, 2022 21:29 UTC	Apellis Pharmaceuticals, Inc. APLS · Entity 47322	SaleCommon Stock	1,250	$45.43	$56,787.50	Disclosure SEC source: 0001127602-22-005298 · form4.xml · nonDerivative · entry 2 Machiels Alec · CIK 0001496687 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 673,774 F1 · kind: This is a scheduled exercise and sale from 10B5-1 trading plan. Read SEC document
February 15, 2022 Filed Feb 16, 2022 21:29 UTC	Apellis Pharmaceuticals, Inc. APLS · Entity 47322	Exercise / conversionCommon Stock	1,250	$2.67	$3,337.50	Disclosure SEC source: 0001127602-22-005298 · form4.xml · nonDerivative · entry 1 Machiels Alec · CIK 0001496687 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 675,024 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is a scheduled exercise and sale from 10B5-1 trading plan. Read SEC document
January 14, 2022 Filed Jan 20, 2022 01:15 UTC	Apellis Pharmaceuticals, Inc. APLS · Entity 47322	Exercise / conversionStock Option(Right to Buy) · Derivative	1,250	$0.00 Strike: $2.67	$0.00	Disclosure SEC source: 0000899243-22-002522 · doc4.xml · derivative · entry 4 Machiels Alec · CIK 0001496687 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,279 Underlying: Common Stock · 1,250 shares Expires 2023-12-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is a scheduled exercise and sale from 10B5-1 trading plan. F3 · derivative.exercise_date: This option was granted on December 5, 2013 and fully vested. Read SEC document
January 14, 2022 Filed Jan 20, 2022 01:15 UTC	Apellis Pharmaceuticals, Inc. APLS · Entity 47322	SaleCommon Stock	1,250	$40.56	$50,700.00	Disclosure SEC source: 0000899243-22-002522 · doc4.xml · nonDerivative · entry 2 Machiels Alec · CIK 0001496687 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 673,774 F1 · kind: This is a scheduled exercise and sale from 10B5-1 trading plan. Read SEC document
January 14, 2022 Filed Jan 20, 2022 01:15 UTC	Apellis Pharmaceuticals, Inc. APLS · Entity 47322	Exercise / conversionCommon Stock	1,250	$2.67	$3,337.50	Disclosure SEC source: 0000899243-22-002522 · doc4.xml · nonDerivative · entry 1 Machiels Alec · CIK 0001496687 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 675,024 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is a scheduled exercise and sale from 10B5-1 trading plan. Read SEC document
January 01, 2022 Filed Jan 5, 2022 02:28 UTC	Apellis Pharmaceuticals, Inc. APLS · Entity 47322	GrantStock Option (Right to Buy) · Derivative	8,554	$0.00 Strike: $47.28	$0.00	Disclosure SEC source: 0001127602-22-000725 · form4.xml · derivative · entry 3 Machiels Alec · CIK 0001496687 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,554 Underlying: Common Stock · 8,554 shares Expires 2029-12-31 F3 · derivative.exercise_date: This represents a non-qualified stock option grant made on 1/1/2022 that vests quarterly over 1 year from the date of grant, subject to continued service as a director, and expires seven years from the date of grant. Read SEC document
January 01, 2022 Filed Jan 5, 2022 02:28 UTC	Apellis Pharmaceuticals, Inc. APLS · Entity 47322	GrantCommon Stock	4,230	$0.00	$0.00	Disclosure SEC source: 0001127602-22-000725 · form4.xml · nonDerivative · entry 1 Machiels Alec · CIK 0001496687 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 673,774 F1 · kind: This represents a restricted stock unit grant made on 1/1/2022 that fully vest on the first anniversary of the date of grant, subject to continued service as a director. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.